SEED Discloses Novel Molecular Glue IND Candidate at “TPD Think Tank” Symposium.
SEED Achieved 3rd Milestone with Lilly R&D Collaboration in March 2024.
SEED Therapeutics’ Mission
To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.
Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation. SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.
DRUG DISCOVERY
SEED Therapeutics: A focus on Molecular Glues
SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”
PIPELINE
THE TEAM
Click below to learn more about SEED Therapeutics’ leadership
NEWSROOM
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASESBeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to...
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASESSeed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer “Molecular Glue” Protein Degradation Serves as Alternative Approach for...
Events